63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
7 citations
,
January 2017 in “Annals of Dermatology” Oral cyclosporine combined with Pantogar® effectively treats twenty-nail dystrophy.
10 citations
,
July 2016 in “Clinical and translational science” Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
February 2010 in “Journal of The American Academy of Dermatology” Posaconazole is a promising new treatment for toenail fungus.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
February 2023 in “Reactions Weekly”
1 citations
,
February 2018 in “Orthopedics and rheumatology” Combining Western chemotherapy with Traditional Chinese Medicine can reduce side effects and improve immune response in treating bone and soft tissue tumors.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
July 2024 in “Reactions Weekly” 1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
4 citations
,
December 2024 in “JAAD Case Reports” Nirogacestat can cause severe skin issues like hidradenitis suppurativa.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
The treatment was ineffective in humans.
January 2023 in “Cutaneous and Ocular Toxicology”
1 citations
,
October 2023 in “Life science alliance” Pantethine may boost the immune system's ability to fight sarcoma.
52 citations
,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
32 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Skin reactions from cancer treatments might predict how well the treatments work.